Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

19
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
19
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

839
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
839
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

12
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
12
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

13
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
13
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

19
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
19
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

57
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
57

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-IT.

American journal of preventive cardiology·2026
Same author

Long-term amyloid PET and MRI outcomes in a menopausal hormone therapy trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM.

American journal of preventive cardiology·2026
Same author

Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT.

European journal of preventive cardiology·2026
Same author

Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.

Atherosclerosis·2026
Same author

Association between central adiposity and cognitive domain function in recently postmenopausal women: an analysis from the KEEPS-Cog substudy of the Kronos Early Estrogen Preventive Study.

Menopause (New York, N.Y.)·2025

Related Experiment Video

Updated: Apr 26, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.4K

Hyperlipoproteinemia type 3: the forgotten phenotype.

Paul N Hopkins1, Eliot A Brinton, M Nazeem Nanjee

  • 1Cardiovascular Genetics, Department of Internal Medicine, University of Utah, 420 Chipeta Way, Room 1160, Salt Lake City, UT, 84108, USA, paul.hopkins@utah.edu.

Current Atherosclerosis Reports
|August 1, 2014
PubMed
Summary

Hyperlipoproteinemia type 3 (HLP3) results from impaired triglyceride-rich lipoprotein removal, causing dangerous remnant buildup. Early diagnosis and treatment are crucial but often missed due to low awareness and infrequent diagnostic testing.

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

7.5K
The Isolation of Flowing Mesenteric Lymph in Mice to Quantify In Vivo Kinetics of Dietary Lipid Absorption and Chylomicron Secretion
06:14

The Isolation of Flowing Mesenteric Lymph in Mice to Quantify In Vivo Kinetics of Dietary Lipid Absorption and Chylomicron Secretion

Published on: November 30, 2022

3.4K

Related Experiment Videos

Last Updated: Apr 26, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.4K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

7.5K
The Isolation of Flowing Mesenteric Lymph in Mice to Quantify In Vivo Kinetics of Dietary Lipid Absorption and Chylomicron Secretion
06:14

The Isolation of Flowing Mesenteric Lymph in Mice to Quantify In Vivo Kinetics of Dietary Lipid Absorption and Chylomicron Secretion

Published on: November 30, 2022

3.4K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Metabolic Disorders

Background:

  • Hyperlipoproteinemia type 3 (HLP3) is characterized by the accumulation of abnormal triglyceride-rich lipoprotein (TGRL) remnants, known as β-VLDL.
  • Elevated β-VLDL levels are associated with significant health risks, including tuberous xanthomas, atherosclerosis, and premature coronary artery disease.

Purpose of the Study:

  • To highlight the genetic and molecular underpinnings of HLP3, emphasizing the potential involvement of numerous genes.
  • To underscore the importance of recognizing HLP3's prevalence and the need for improved diagnostic approaches.

Main Methods:

  • Review of recent genetic and molecular studies.
  • Analysis of factors contributing to impaired hepatic TGRL processing and increased TGRL production.
  • Assessment of HLP3 prevalence and diagnostic challenges.

Main Results:

  • HLP3 involves impaired TGRL removal, leading to the accumulation of atherogenic β-VLDL.
  • Multiple genes likely contribute to HLP3, affecting hepatic TGRL processing or production.
  • HLP3 is often underdiagnosed despite being treatable.

Conclusions:

  • HLP3 poses significant cardiovascular risks due to TGRL remnant accumulation.
  • Increased awareness and utilization of definitive diagnostic methods are essential for timely HLP3 diagnosis and management.
  • Genetic and molecular insights are expanding our understanding of HLP3's complex etiology.